OBI presented its Obrion™ ADC technologies at AntibodyChina 2026, highlighting process scale-up, clinical supply feasibility, and GlycOBI DUO® dual-payload design.
🔗 www.obipharma.com/news/antibod...

#OBIPharma #AntibodyChina2026 #ADC #Obrion #GlycOBI #DualPayload #Shanghai

🚀 OBI Pharma has signed an exclusive global license agreement with TegMine Therapeutics, Inc. for a glycan-targeting ADC.
#OBIPharma #TegMine #ADC #Oncology #GlycOBI #CancerTherapy #Biotech #Partnership

www.accessnewswire.com/newsroom/en/...

🤝浩鼎與美國 TegMine Therapeutics 簽訂受其委託開發之醣蛋白 ADC 全球專屬授權合約
🌏此次國際授權合作，展現以浩鼎 Obrion™ ADC 技術所開發產品的應用前景🚀
#OBIPharma #Obrion #GlycOBI #Glycoprotein #ADC #ExclusiveLicense #GlobalPartnership

www.obipharma.com/zh-hant/news...

🎉 OBI-902 receives a Second FDA Orphan Drug Designation, this time for gastric cancer including gastroesophageal junction adenocarcinoma.
We remain committed to advancing OBI-902 in areas of high unmet medical need. 🔬
#ADC #OBI902 #TROP2 #GlycOBI #ODD #GC #GEJC

www.obipharma.com/news/obi-902...

OBI Pharma is excited to announce a technology collaboration with AP Biosciences, Inc. to develop a next-generation bispecific Antibody-Drug Conjugate (ADC). 🤝
🔗 Learn more: www.obipharma.com/news/obi-pha...

#OBIPharma #APBiosciences #ADC #GlycOBI #Innovation #Partnership

🚀 OBI Pharma has enrolled the first patient in our Phase 1/2 clinical trial of OBI-902, our first TROP2-targeted ADC built with our proprietary GlycOBI® technology.
🔗 Learn more: www.globenewswire.com/news-release...
#OBIPharma #ADC #ClinicalTrials
#GlycOBI #OBI902 #Phase1 #firstpatientin

On 7/28, OBI welcomed the 2025 BIO Asia–Taiwan tour at Taipei Bioinnovation Park. Guests toured our Enzyme, CMC, Biology, and QC labs, exploring our ADC research. Thanks to our team for showcasing OBI’s next-gen therapeutics! #OBIPharma #BIOAsiaTaiwan2025 #TBIP #ADC #LabTour #GlycOBI

OBI Pharma at #BIOAsia2025
7/24, our CEO Dr. Heidi Wang moderated two high-impact sessions (A-6 & A-7) at the 2025 Innovation Forum
#GlycOBI #ADC #OBIPharma #DualPayload #InnovationForum #AntibodyConjugates #InnovationLeadership #Biotech #BIOAsia2025

【BIO Asia–Taiwan 2025｜the Investment Summit】
Today (7/23), our CEO Dr. Heidi Wang joined the Investment Summit on the 7th floor of the TaiNEX2, delivering OBI Pharma’s roadshow presentation.
#BIOAsiaTaiwan2025
#OBIPharma #ADC #GlycOBI #PrecisionMedicine #InvestmentSummit

浩鼎自創ADC平台GlycOBI® 首宗技術合作案🤝
OBI Pharma Enters ADC Collaboration with Tegmine Therapeutics! 🤝 🚀
#OBIPharma #TegMineTherapeutics #ADCCollaboration #GlycOBI #CancerTherapies

🔬 Learn more:
📄 English Press Release: lnkd.in/gprWcZ7D
📄 中文新聞稿: lnkd.in/gqEqredN

台灣浩鼎藥物化學處資深處長黃鐙毅 (David Teng-Yi Huang) 於「2025 ATC抗體藥物暨第20屆前瞻生物醫學科學新知研討會」分享GlycOBI®技術與HYPrOBI™連接子創新！

#ATC2025 #ADC #GlycOBI #HYPrOBI #浩鼎 #癌症治療

news.gbimonthly.com/tw/article/s...

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC - OBI Pharma 台灣浩鼎 OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology. TAIPEI, Taiwan, May 1, 2025 — OBI Pharma, Inc. （“OBI”）, a clinical stage oncology company （4174.TWO）, today...

🔔U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902
OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology.
#ADC #GlycOBI #Trop2 #OBIPharma #INDClearance

Learn more:
www.obipharma.com/news/obi-pha...

🔬 4th Novel Conjugates Summit 🚀
🌍At the 4th Novel Conjugates Summit in Boston 🏙️, OBI showcased GlycOBI®, our innovative ADC platform.

🔗 Learn more: www.obipharma.com/news/glycobi...

#OBIPharma #ADC #GlycOBI
#NovelConjugatesSummit #ADCDevelopment
#GlycanConjugation #BsADC #DualPayload